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 Th e hemolytic uremic syndrome (HUS, 
MIM 235,400) is a condition character-
ized by thrombocytopenia, microangio-
pathic hemolytic anemia, and acute renal 
failure due to glomerular thrombotic 
microangiopathy. Th e majority of HUS 
episodes are triggered by  Escherichia coli 
0157:H7 infection. However, a minority 
of cases are not associated with infection; 
this form, termed atypical HUS (aHUS), 
has the poorest long-term prognosis. Dur-
ing the last decade there has been dra-
matic progress in understanding the 
pathogenesis of aHUS, particularly 
through the study of familial forms. 
Approximately half of all aHUS cases have 
been associated with mutations and / or 
polymorphisms in genes encoding pro-
teins of the complement system. Muta-
tions in the regulatory proteins of this 
system resulted in  ‘ loss of function, ’ 
whereas mutations in genes encoding 
complement activation proteins resulted 
in  ‘ gain of function. ’ 1 Mutations in throm-
bomodulin, an endothelial glycoprotein, 
have recently been associated with aHUS. 2 
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 Mutations in the  complement factor H ( CFH ) gene are frequently 
associated with atypical hemolytic uremic syndrome (aHUS). Hakobyan 
 et al. have developed novel reagents that can rapidly determine the 
contribution of each  CFH allele to the total plasma  CFH pool, showing 
that low-expression  CFH alleles are important risk factors for the 
development of aHUS. These reagents represent a significant 
contribution to the techniques used to determine susceptibility factors 
among individuals with aHUS. 
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These mutations were associated with 
impaired complement regulation  in vitro . 
Together with other lines of evidence, 
aHUS is now viewed as a disorder in 
which there is defective complement reg-
ulation ( Figure 1 ). 
 In many individuals, both genetic sus-
ceptibility factors and an environmental 
insult are required for the syndrome to 
develop. For example, many environmen-
tal factors — such as infection, pregnancy, 
and drugs — have been reported to trigger 
episodes of aHUS. 1 Family studies have 
clearly shown that multiple genetic risk 
factors are generally required for the con-
dition to become manifest. For example, 
in one pedigree in which there were three 
independently segregating aHUS-associ-
ated risk factors, the syndrome developed 
only among individuals possessing all 
three risk factors. 3 
 Th e investigation of individuals with 
aHUS for genetic susceptibility factors 
has become increasingly complex 
because both the number and nature of 
reported genetic defects has expanded. 
Th e diagnostic workup of aff ected indi-
viduals is summarized in  Figure 2 . Exon 
sequencing to screen for mutations in 
complement regulatory ( CFH, CFI, and 
 MCP (membrane cofactor protein, also 
known as CD46)) and activation ( C3, 
CFB ) genes and the thrombomodulin 
gene ( THRB ) is relatively straightfor-
ward. However, signifi cant complexity 
arises within the  CFH gene family. Com-
plement factor H (CFH) is the major 
regulator of the complement alternative 
pathway, and mutations in the  CFH gene 
are among the most frequent alterations 
detected in the majority of aHUS 
cohorts. Th e  CFH gene is located in the 
 ‘ regulators of complement activation ’ 
(RCA) gene cluster on chromosome 
1q32. 4 Th e gene encodes the CFH pro-
tein, an abundant plasma protein com-
prising 20 globular domains termed 
short consensus repeat (SCR) domains. 
In addition, through alternative splicing, 
the  CFH gene also encodes a smaller 
protein consisting of only seven SCR 
domains, termed factor H – like 1 (FHL-1). 
With the exception of the C-terminal 
four amino acids, the FHL-1 protein 
sequence is identical to the fi rst seven 
SCR domains of CFH. In close proximity 
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to the  CFH locus are fi ve genes encoding 
proteins that are structurally related to 
CFH. These five proteins are termed 
CFH-related proteins. Th eir respective 
genes are arranged in the genomic 
sequence  CFHR3 ,  CFHR1 ,  CFHR2 , 
 CFHR4, and  CFHR5. Th e  CFH – CFHR1 – 5 
gene region contains multiple genomic 
duplications that render this area suscep-
tible to genomic rearrangements through 
mechanisms such as gene conversion or 
nonhomologous recombination. Some of 
these rearrangements have been associ-
ated with aHUS. Examples include a 
rearrangement that results in the forma-
tion of a  CFH – CFHR1 hybrid gene. 5 Fur-
thermore, a common polymorphic 
rearrangement that results in the dele-
tion of  CFHR1 and  CFHR3 genes is asso-
ciated with anti-CFH autoantibodies and 
aHUS. 6,7 Identification of these rear-
rangements requires the use of techniques 
(such as multiplex ligation-dependent 
probe amplifi cation analysis) that assess 
copy-number variation across the  CFH –
 CFHR1 – 5 gene region. 
 In addition to genetic analysis, impor-
tant investigations in aHUS patients 
include assays to measure plasma com-
plement components (e.g., CFH), meas-
urement of CD46 expression on 
peripheral blood mononuclear cells, and 
techniques to detect anti-CFH autoanti-
bodies. Again, the situation for CFH is 
not straightforward. Th e normal range 
for plasma CFH is quite wide and infl u-
enced by both genetic and environmen-
tal (e.g., smoking) factors. 8 Consequently, 
heterozygous CFH defi ciency states may 
not be readily detectable by measurement 
of plasma CFH levels. Th e diffi  culty is how 
to distinguish the contribution of each 
 CFH allele to the plasma CFH pool. 
 In this issue, Hakobyan  et al. 9 report 
having addressed this problem by devel-
oping a novel method to rapidly measure 
allele-specific CFH protein products 
( Figure 3 ). Th ey used the common non-
synonymous CFH polymorphism termed 
Y402H (rs1061170), located within the 
SCR7 domain of both CFH and FHL-1, to 
generate monoclonal antibodies specifi c 
for either the Y402 or H402 protein allo-
types. Th ese reagents allowed the authors 
to determine, among individuals who are 
heterozygous for Y402H, the contribution 
of each  CFH allele to the total plasma CFH 
and FHL-1 protein pool. With these new 
tools, they assessed plasma levels of the 
Y402 and H402 protein allotypes among 
individuals with aHUS in their Spanish 
cohort. Among 48 cases who were hetero-
zygous for Y402H, 3 unrelated individuals 
with low expression of the H402 allele 
were identifi ed. In 2 of these (H29 and H90), 
total plasma CFH levels were in the lower 
part of the normal range (124.4 – 402  mg /
 liter) when a non-allele-specifi c CFH ELISA 
was used. In each family, the inheritance 
of low- or null-expression alleles was an 
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 Figure 2  |  Investigations in atypical hemolytic uremic syndrome. The laboratory workup 
of these patients comprises mutation screening, determining levels of complement proteins 
in plasma, and testing for autoantibodies to complement factor H (CFH). Mutation screening 
comprises direct exon sequencing of the six disease-associated genes identified to date together 
with assays that can identify the  CFH hybrid gene. MCP is a membrane-bound complement 
regulator; hence expression is determined on peripheral blood mononuclear cells. The plasma 
levels of Y402 and H402 variants of CFH (red box) can be quantified by using a new ELISA assay 












 Figure 1  |  Complement mutations in atypical hemolytic uremic syndrome. This syndrome is 
due to impaired regulation of complement activation along the renal endothelium. This occurs 
because of loss-of-function mutations in complement regulatory genes or gain-of-function 
mutations in complement activation protein genes. Mutations in the thrombomodulin gene also 
appear to result in impaired complement regulation. In some individuals, more than one of these 
factors is present. CFB, complement factor B; CFH, complement factor H; CFI, complement factor I; 
MCP, membrane cofactor protein (CD46); THRB, thrombomodulin. 
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independent risk factor for aHUS. Several 
important messages emerged from the 
analysis of these individuals. 
 First, using an ELISA assay, these anti-
bodies provide a rapid and simple tool for 
the identifi cation of  CFH null alleles. In 
addition, these novel reagents may cir-
cumvent the need to perform cloning and 
expression studies to determine whether 
a particular mutant aff ects protein expres-
sion. Two of the index cases identifi ed by 
Hakobyan  et al. 9 were found to have muta-
tions aff ecting cysteine residues within the 
CFH protein (C853R in index case H90 
and C1218R in index case H169). Both 
index cases were heterozygous for the 
Y402H polymorphism. With the allotype-
specifi c reagents developed by Hakobyan 
 et al. , 9 it was straightforward to demon-
strate that these cysteine mutations are 
associated with no expression of the CFH 
protein. Using western blotting, it was also 
possible to show that FHL-1 expression 
from the aff ected alleles was normal. Th is 
would be expected, since these cysteine 
mutations aff ected exons encoding for 
SCR domains that are not present in the 
FHL-1 protein. In another report, these 
reagents were used to demonstrate that 
the CFH Y899D mutation was associated 
with minimal protein expression. 10 
 Second, these techniques allowed Hako-
byan  et al. 9 to track two abnormal  CFH 
alleles in another aHUS-aff ected pedigree. 
Th e index case (H29), a Y402H heterozy-
gote, had low levels of the plasma H402 
protein allotype. In contrast, plasma levels 
of the Y402 protein allotype were normal. 
However, this individual carried a com-
mon aHUS-associated  CFH gene muta-
tion (R1210C) on the  CFH Y402 allele. 
Th e R1210C mutation was present in het-
erozygosity in fi ve other members of this 
pedigree, none of whom had developed 
aHUS. Two of these individuals, one the 
sister of the index case, were Y402H het-
erozygotes. Hakobyan  et al. 9 were able to 
show that these individuals had not inher-
ited the abnormal low-expressing  CFH 
H402 allele present in the H29 index case. 
Therefore, in this pedigree, aHUS had 
developed only when both abnormal  CFH 
alleles were present. Only through the use 
of these novel reagents was it possible to 
conclude that the sister of the index case 
is not at high risk of developing aHUS. 
Th is illustrates an important clinical appli-
cation for these antibodies. 
 Th ird, interesting insights into the diff er-
ential regulation of CFH and FHL-1 
emerged from the study of the H29 pedi-
gree. Th e genetic basis of the low-expression 
 CFH H402 allele was not found, even 
though an extensive search for the causative 
mutation was performed. However, 
although the plasma levels of the CFH 402H 
allotype were markedly reduced, western 
blot analysis surprisingly showed that the 
FHL-1-H402 allotype was increased fi ve-
fold compared with controls. Th is suggests 
that the defect has disrupted diff erential 
 CFH gene splicing. Th e signifi cance of this 
is not clear but warrants further study. 
 In summary, the investigation of 
patients with aHUS has become increas-
ingly complex, and in many cases no 
susceptibility factors have been identifi ed. 
Th is indicates that our understanding of 
the condition remains incomplete. Th e 
work of Hakobyan  et al. 9 provides valuable 
additional tools for the investigation of 
patients with aHUS. With the novel rea-
gents developed by these investigators, it 
is now possible to rapidly identify low-
expressing or null  CFH alleles. Th ese are 
independent risk factors for aHUS that 
should be looked for in other cohorts. 
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 Figure 3  |  Complement factor H and the Y402H polymorphism. Complement factor H (CFH) is a 
plasma protein comprising 20 globular protein domains termed short consensus repeat domains 
(SCRs). Distinct SCRs mediate the important functions of CFH. Regulation of C3 is mediated by 
the initial four amino terminal domains (colored red), and surface recognition domains include 
terminal two carboxyl domains (green). The Y402H polymorphism (T1204C, rs1061170) is located 
within SCR domain 7. Hakobyan  et al. 9 have generated antibodies that specifically recognize either 
the Y402 or H402 CFH and FHL-1 variants. Among individuals who are heterozygous for the Y402H 
polymorphism (and thus have both 402H CFH and 402Y CFH in plasma), the novel antibodies 
enable investigators to determine the contribution of each of the two CFH alleles to the total 
plasma CFH pool. This facilitates rapid detection of CFH null alleles. 
